Cross-sectional HIV incidence estimation in HIV prevention research

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue SUPPL. 2, 2013, Pages

  Brookmeyer, Ron ^a   Laeyendecker, Oliver ^b,c   Donnell, Deborah ^d   Eshleman, Susan H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cross sectional; HIV; Incidence; Multiassay algorithm

Indexed keywords

ALGORITHM; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DRUG SCREENING; GENETIC VARIABILITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOASSAY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIORITY JOURNAL; SEROCONVERSION; SOCIAL SUPPORT; VIRUS LOAD; VIRUS TRANSMISSION;

ALGORITHMS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; LIMIT OF DETECTION; MODELS, STATISTICAL; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK FACTORS; UNITED STATES; VIRAL LOAD;

EID: 84880070553     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182986fdf     Document Type: Article

References (54)

1. Lagakos SW, Gable AR. Challenges to HIV prevention-seeking effective measures in the absence of a vaccine. N Engl J Med. 2008;358: 1543-1545.
2. Institute of Medicine. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press; 2008.
3. De Amici D, Klersy C, Ramajoli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Control Clin Trials. 2000;21:103-114.
4. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995;141:166-172.
5. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
6. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
7. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill. 2008;13. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18966.
8. Guy R, Gold J, Calleja JM, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis. 2009;9:747-759.
9. UNAIDS Reference Group on Estimates, Modeling and Projections- Statement on the use of the BED assay for estimation of HIV-1 incidence or epidemic monitoring. Wkly Epidemiol Rec. 2006; 81: 33-40.
10. Laeyendecker O, Brookmeyer R, Cousins MM, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis. 2013;207:232-239.
11. Eshleman SH, Hughes JP, Laeyendecker O, et al. Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis. 2013;207:223-231.
12. Brookmeyer R, Konikoff J, Laeyendecker O, et al. HIV incidence estimation using multiple biomarkers. Am J Epidemiol. 2013;177: 264-272.
13. Mastro TD. Determining HIV incidence in populations: moving in the right direction. J Infect Dis. 2013;207:204-206.
14. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2:e1312.
15. Graham SM, Shah PS, Aesch ZC, et al. A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power. HIV Clin Trials. 2009;10:413-431.
16. Latkin CA, Donnell D, Metzger D, et al. The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Soc Sci Med. 2009;68:740-748.
17. Sweat M, Morin S, Celentano D, et al. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis. 2011;11:525-532.
18. Khumalo-Sakutukwa G, Morin SF, Fritz K, et al. Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr. 2008;49:422-431.
19. Bollinger RC, Brookmeyer RS, Mehendale SM, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA. 1997;278:2085-2089.
20. Pilcher CD, Eron JJ Jr, Galvin S, et al. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004;113:937-945.
21. ICF International. HIV Prevalence Estimates from the Demographic and Health Surveys. Calverton, MD: ICF International; 2012. Available at: http://measuredhs.com. Accessed January 3, 2013.
22. Brookmeyer R, Konikoff J. Statistical considerations in determining HIV incidence from changes in HIV prevalence. Stat Commun Infect Dis. 2011, 3:Article 9.
23. Freeman J, Hutchison GB. Prevalence, incidence and duration. Am J Epidemiol. 1980;112:707-723.
24. Cole SR, Chu H, Brookmeyer R. Confidence intervals for biomarker-based human immunodeficiency virus incidence estimates and differences using prevalent data. Am J Epidemiol. 2007;165:94-100.
25. Brookmeyer R. Accounting for follow-up bias in estimation of human immunodeficiency virus incidence rates. J R Stat Soc. 1997;160: 127-140.
26. Kaplan E, Brookmeyer R. Snapshot estimators of recent HIV incidence rates. Oper Res. 1999;47:29-37.
27. Brookmeyer R. On the statistical accuracy of biomarker assays for HIV incidence. J Acquir Immune Defic Syndr. 2010;54:406-414.
28. Coates T, Eshleman SH, Chariyalertsak S, et al. Findings on estimates of community-level HIV incidence in HPTN 043 (Project Accept). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA. Abstract 30.
29. Young CL, Hu DJ, Byers R, et al. Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses. 2003;19:481-486.
30. Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr. 2003;32:424-428.
31. Masciotra S, Dobbs T, Candal D, et al. Antibody avidity-based assay for identifying recent HIV-1 infections based on Genetic Systems TM 1/2 plus O EIA. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010. Abstract 937.
32. Barin F, Meyer L, Lancar R, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol. 2005;43:4441-4447.
33. Curtis KA, Kennedy MS, Charurat M, et al. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum Retroviruses. 2012;28:188-197.
34. Dobbs T, Kennedy S, Pau CP, et al. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol. 2004;42:2623-2628.
35. Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses. 2010;26:61-71.
36. Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012;7: e33328.
37. Laeyendecker O, Brookmeyer R, Oliver AE, et al. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses. 2012;28:816-822.
38. Laeyendecker O, Rothman RE, Henson C, et al. The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr. 2008; 48:211-215.
39. Wendel SK, Mullis CE, Eshleman SH, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in individuals with clade B HIV infection. PLoS One. 2013;8:e55525.
40. Hayashida T, Gatanaga H, Tanuma J, et al. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immuno-assay. AIDS Res Hum Retroviruses. 2008;24:495-498.
41. Mastro TD, Kim AA, Hallett T, et al. Estimating HIV incidence in populations using tests for recent infection: issues, challenges and the way forward. J HIV AIDS Surveill Epidemiol. 2010;2:1-14.
42. Parekh BS, Hanson DL, Hargrove J, et al. Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses. 2011;27:265-273.
43. Mullis C, Munshwa S, Grabowski M, et al. HIV sequence differences are associated with false-recent misclassification with the BED capture enzyme immunoassay in subtype D HIV. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Abstract 541.
44. CEPHIA. Consortium for the evaluation and performance of HIV incidence assays. Available at: http://www.incidence-estimation.com/page/-homepage. Accessed January 3, 2013.
45. Laeyendecker O, Wang L, Hughes JP, et al. Use of a multi-assay algorithm for cross-sectional HIV incidence estimation in HPTN 061 (the Brothers Study). Paper presented at: 20th Conference on Retrovi-ruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA. Abstract 1053.
46. Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS. 2010;24:2763-2771.
47. Rehle TM, Hallett TB, Shisana O, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One. 2010;5:e11094.
48. Kahle E, Kashuba A, Baeten J, et al. Unreported antiretroviral use by HIV-1 infected members of HIV-1 serodiscordant couples enrolling in an HIV-1 prevention clinical trial. Paper presented at: International Micro-bicides Conference; April 15-18, 2012; Sydney, Australia.
49. Marzinke MA. Development and validation of a high resolution accurate mass method for the multiplexed monitoring of antiretroviral agents in human serum. Academy of Clinical Laboratory Physicians and Scientists, 47th National Meeting, June 2012; Milwaukee, WI.
50. Laeyendecker O, Piwowar-Manning E, Fiamma A, et al. Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH Project Accept (HIV Prevention Trials Network 043). PLoS One. 2013. In Press.
51. Cousins MM, Laeyendecker O, Beauchamp G, et al. Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One. 2011;6: e27211.
52. Cousins MM, Ou SS, Wawer MJ, et al. Comparison of a high-resolution melting assay to next-generation sequencing for analysis of HIV diversity. J Clin Microbiol. 2012;50:3054-3059.
53. Hodder SL, Justman J, Hughes JP, et al. HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med. 2013;158:10-18.
54. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001; 183:23-35.